Compare SCM & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCM | CTKB |
|---|---|---|
| Founded | 2012 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 433.8M |
| IPO Year | 2012 | 2021 |
| Metric | SCM | CTKB |
|---|---|---|
| Price | $12.51 | $5.20 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.00 | $5.88 |
| AVG Volume (30 Days) | 212.6K | ★ 1.9M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | ★ 12.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | $102,538,895.00 | ★ $196,828,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | $11.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.19 | $2.37 |
| 52 Week High | $15.56 | $7.30 |
| Indicator | SCM | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 60.12 | 53.94 |
| Support Level | $11.93 | $5.15 |
| Resistance Level | $12.28 | $5.50 |
| Average True Range (ATR) | 0.29 | 0.43 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 96.10 | 33.33 |
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.